progression-free survival Archives

How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways

By Pallavi Madhiraju on March 21, 2026 Pharma & Biotech

Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.

J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results

By Pallavi Madhiraju on March 6, 2026 Pharma & Biotech

FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.

Scancell’s late-stage push for iSCIB1+ reframes the risk calculus in advanced melanoma trials

By Soujanya Ravi on January 26, 2026 Pharma & Biotech

FDA clears Scancell’s iSCIB1+ for Phase 3 testing in advanced melanoma. Discover what this means for immunotherapy risk, trial design, and competition.